A detailed history of First Turn Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, First Turn Management, LLC holds 67,942 shares of KRYS stock, worth $11.4 Million. This represents 1.96% of its overall portfolio holdings.

Number of Shares
67,942
Previous 109,222 37.79%
Holding current value
$11.4 Million
Previous $20.1 Billion 38.34%
% of portfolio
1.96%
Previous 3.26%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$174.7 - $213.66 $7.21 Million - $8.82 Million
-41,280 Reduced 37.79%
67,942 $12.4 Billion
Q2 2024

Aug 07, 2024

SELL
$153.12 - $183.64 $3.31 Million - $3.97 Million
-21,628 Reduced 16.53%
109,222 $20.1 Billion
Q1 2024

May 03, 2024

SELL
$108.01 - $179.35 $12 Million - $20 Million
-111,335 Reduced 45.97%
130,850 $23.3 Billion
Q4 2023

Feb 07, 2024

BUY
$96.0 - $128.29 $23.2 Million - $31.1 Million
242,185 New
242,185 $30 Billion

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.3B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track First Turn Management, LLC Portfolio

Follow First Turn Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Turn Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Turn Management, LLC with notifications on news.